Media Release COPENHAGEN, Denmark; June 2, 2024 Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of follicular lymphoma (FL). A preliminary analysis of data from the EPCORE™ NHL-2 study (NCT04663347),…
Tue, 22 Oct 2024 04:15:00 GMT Drill core samples from the 2024 drill program at Hatchet have been sent to the SRC Geoanalytical Laboratories in Saskatoon, Saskatchewan for analysis. The results discussed in this news release are ...
Tue, 15 Oct 2024 06:01:00 GMT The Company's unaudited preliminary estimated financial results are based on information available to us as of the date of this press release ... for supplemental analysis. In evaluating the ...
Tue, 15 Oct 2024 05:02:00 GMT The unaudited preliminary estimated financial information included in this press release has been prepared ... them appropriate for supplemental analysis. In evaluating the non-GAAP financial ...
Wed, 25 Sep 2024 17:01:00 GMT Today, the Company announced preliminary data from 21 patients assessed at three months ... Some of the statements contained in this press release may constitute forward-looking statements within the ...
Sun, 22 Sep 2024 17:01:00 GMT On September 23, the American Library Association (ALA) released preliminary data documenting attempts ... To access the ALA press release about this data, visit ALA’s News and Press Center.
